Aurelien Belot

Dr. Aurelien Belot

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2008 in Revue D'Épidémiologie Et de Santé Publique
Verified
Journal Article
Closed access
ABAurelien Belot
Aurelien Belot
PGpascale grosclaude
pascale grosclaude
NBN. Bossard
N. Bossard
EJE. Jougla
E. Jougla
EBE. Benhamou
E. Benhamou
MVM. Velten
M. Velten

1 October 2015 in European Journal of Cancer
Verified
Journal Article
Closed access
Gemma GattaGemma Gatta
Gemma Gatta
LBLaura Botta
Laura Botta
María-José SánchezMaría-José Sánchez
María-José Sánchez
LALesley Ann Anderson
Lesley Ann Anderson
Daniela PierannunzioDaniela Pierannunzio
Daniela Pierannunzio
ROR. Otter
R. Otter

28 January 2020 in BMC Cancer
Verified
Journal Article
Open access
PDF file
HFHelen Fowler
Helen Fowler
ABAurelien Belot
Aurelien Belot
LELibby Ellis
Libby Ellis
CMCamille Maringe
Camille Maringe
MLMiguel Angel Luque-Fernandez
Miguel Angel Luque-Fernandez
BRBernard Rachet
Bernard Rachet
Background: The presence of comorbidity affects the care of cancer patients, many of whom are living with multiple comorbidities. The prevalence of cancer comorbidity, beyond summary metrics, is not well known. This study aims to estimate the prevalence of comorbid conditions among cancer patients in England, and describe the association between cancer comorbidity and socio-economic position, using population-based electronic health records. Methods: We linked England cancer registry records of patients diagnosed with cancer of the colon, rectum, lung or Hodgkin lymphoma between 2009 and 2013, with hospital admissions records. A comorbidity was any one of fourteen specific conditions, diagnosed during hospital admission up to 6 years prior to cancer diagnosis. We calculated the crude and age-sex adjusted prevalence of each condition, the frequency of multiple comorbidity combinations, and used logistic regression and multinomial logistic regression to estimate the adjusted odds of having each condition and the probability of having each condition as a single or one of multiple comorbidities, respectively, by cancer type. Results: Comorbidity was most prevalent in patients with lung cancer and least prevalent in Hodgkin lymphoma patients. Up to two-thirds of patients within each of the four cancer patient cohorts we studied had at least one comorbidity, and around half of the comorbid patients had multiple comorbidities. Our study highlighted common comorbid conditions among the cancer patient cohorts. In all four cohorts, the odds of having a comorbidity and the probability of multiple comorbidity were consistently highest in the most deprived cancer patients. Conclusions: Cancer healthcare guidelines may need to consider prominent comorbid conditions, particularly to benefit the prognosis of the most deprived patients who carry the greater burden of comorbidity. Insight into patterns of cancer comorbidity may inform further research into the influence of specific comorbidities on socio-economic inequalities in receipt of cancer treatment and in short-term mortality.

1 October 2015 in European Journal of Cancer
Verified
Journal Article
Closed access
MSMilena Sant
Milena Sant
MLMaria Dolores Chirlaque Lopez
Maria Dolores Chirlaque Lopez
RARoberto Agresti
Roberto Agresti
María-José SánchezMaría-José Sánchez
María-José Sánchez
BHBernd Holleczek
Bernd Holleczek
ROR. Otter
R. Otter

1 August 2013 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
CHChristophe Hennequin
Christophe Hennequin
NBNadine Bossard
Nadine Bossard
SSStéphanie Servagi-Vernat
Stéphanie Servagi-Vernat
PMPhilippe Maingon
Philippe Maingon
JDJean-Bernard Dubois
Jean-Bernard Dubois
PRPascale Romestaing
Pascale Romestaing

9 May 2020 in International Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
CMCamille Maringe
Camille Maringe
SMSara Benitez Majano
Sara Benitez Majano
AEAimilia Exarchakou
Aimilia Exarchakou
MSMatthew Smith
Matthew Smith
BRBernard Rachet
Bernard Rachet
CLClémence Leyrat
Clémence Leyrat
Acquiring real-world evidence is crucial to support health policy, but observational studies are prone to serious biases. An approach was recently proposed to overcome confounding and immortal-time biases within the emulated trial framework. This tutorial provides a step-by-step description of the design and analysis of emulated trials, as well as R and Stata code, to facilitate its use in practice. The steps consist in: (i) specifying the target trial and inclusion criteria; (ii) cloning patients; (iii) defining censoring and survival times; (iv) estimating the weights to account for informative censoring introduced by design; and (v) analysing these data. These steps are illustrated with observational data to assess the benefit of surgery among 70–89-year-old patients diagnosed with early-stage lung cancer. Because of the severe unbalance of the patient characteristics between treatment arms (surgery yes/no), a naïve Kaplan-Meier survival analysis of the initial cohort severely overestimated the benefit of surgery on 1-year survival (22% difference), as did a survival analysis of the cloned dataset when informative censoring was ignored (17% difference). By contrast, the estimated weights adequately removed the covariate imbalance. The weighted analysis still showed evidence of a benefit, though smaller (11% difference), of surgery among older lung cancer patients on 1-year survival. Complementing the CERBOT tool, this tutorial explains how to proceed to conduct emulated trials using observational data in the presence of immortal-time bias. The strength of this approach is its transparency and its principles that are easily understandable by non-specialists.